Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.43 |
| ▸ | HRH2 | P25021 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.39 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27359356 | 0.93 | MAOB (0.44) | HRH3HRH2HRH1ACHEKCNA3 | |
| SCHEMBL9917377 | 0.90 | HRH3 (0.49) | HRH3HRH2HRH1 | |
| SCHEMBL21667892 | 0.90 | HRH3 (0.49) | HRH3HRH2HRH1 | |
| SCHEMBL9917378 | 0.90 | HRH3 (0.49) | HRH3HRH2HRH1 | |
| SCHEMBL9911412 | 0.89 | KDM1A (0.45) | HRH3HRH2HRH1ACHEKCNA3 | |
| SCHEMBL22890929 | 0.85 | HRH3 (0.41) | HRH3HRH2HRH1ACHEKCNA3 | |
| SCHEMBL22890951 | 0.84 | KDM1A (0.38) | HRH3MEN1ALDH1A1KMT2AMAOB | |
| SCHEMBL20698611 | 0.84 | HRH3 (0.43) | HRH3MEN1KMT2AKDM1ASIGMAR1 | |
| SCHEMBL25492956 | 0.84 | SIGMAR1 (0.50) | HRH3HRH2HRH1MEN1ALDH1A1 | |
| SCHEMBL26741730 | 0.82 | MEN1 (0.41) | HRH3HRH2HRH1MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4272825-A2 | MTORC MODULATORS AND USES THEREOF | Aeovian Pharmaceuticals, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| US-20230331737-A1 | MTORC1 MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS, INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230331737-A1 | MTORC1 MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS, INC. | 2023-10-19 | — | — | US | disclosed |
| US-11759458-B2 | Indane-amines as PD-L1 antagonists | CHEMOCENTRYX, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11759458-B2 | Indane-amines as PD-L1 antagonists | CHEMOCENTRYX, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11708326-B2 | Immunomodulator compounds | CHEMOCENTRYX, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11708326-B2 | Immunomodulator compounds | CHEMOCENTRYX, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11702429-B2 | mTORC modulators and uses thereof | AEOVIAN PHARMACEUTICALS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702429-B2 | mTORC modulators and uses thereof | AEOVIAN PHARMACEUTICALS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11691985-B2 | Macrocyclic immunomodulators | CHEMOCENTRYX, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| WO-2020154447-A1 | MTORC MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS, INC. (US) | 2020-07-30 | — | — | WO | disclosed |
| WO-2019165043-A2 | INDANE-AMINES AS PD-L1 ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2019-08-29 | — | — | WO | disclosed |
| US-10392405-B2 | Macrocyclic immunomodulators | CHEMOCENTRYX, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| US-20190144389-A1 | DEUTERATED COMPOUNDS AS IMMUNOMODULATORS | CHEMOCENTRYX, INC. | 2019-05-16 | — | — | US | disclosed |
| US-20190135745-A1 | IMMUNOMODULATOR COMPOUNDS | CHEMOCENTRYX, INC. | 2019-05-09 | — | — | US | disclosed |
| WO-2019032547-A1 | MACROCYCLIC IMMUNOMODULATORS | CHEMOCENTRYX, INC. (US) | 2019-02-14 | — | — | WO | disclosed |
| US-20190048022-A1 | MACROCYCLIC IMMUNOMODULATORS | CHEMOCENTRYX, INC. | 2019-02-14 | — | — | US | disclosed |
| EP-0784620-B1 | N-SUBSTITUTED PIPERIDINYL BICYCLIC BENZOATE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 1999-12-08 | — | — | EP | disclosed |
| EP-0784620-A1 | N-SUBSTITUTED PIPERIDINYL BICYCLIC BENZOATE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-07-23 | — | — | EP | disclosed |
| WO-1996010027-A1 | N-SUBSTITUTED PIPERIDINYL BICYCLIC BENZOATE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1996-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135745-A1 | IMMUNOMODULATOR COMPOUNDS | IL2, FCGRT, IFNG | HRH3 143/4885HRH2 110/4885HRH1 166/4885 |
| US-11708326-B2 | Immunomodulator compounds | IL2, FCGRT, IFNG | HRH3 143/4885HRH2 110/4885HRH1 166/4885 |
| US-20190144389-A1 | DEUTERATED COMPOUNDS AS IMMUNOMODULATORS | C3AR1, C5AR1, C5AR2 | HRH3 14/4885HRH2 38/4885HRH1 29/4885 |
| US-11702429-B2 | mTORC modulators and uses thereof | MTOR, RICTOR, RPTOR | HRH3 3363/4885HRH2 3574/4885HRH1 3452/4885 |
| US-11691985-B2 | Macrocyclic immunomodulators | IL2, IL2RA, C3AR1 | HRH3 162/4885HRH2 158/4885HRH1 234/4885 |
| US-20190048022-A1 | MACROCYCLIC IMMUNOMODULATORS | IL2, IL2RA, C3AR1 | HRH3 162/4885HRH2 158/4885HRH1 234/4885 |
| US-10392405-B2 | Macrocyclic immunomodulators | IL2, IL2RA, C3AR1 | HRH3 162/4885HRH2 158/4885HRH1 234/4885 |
| US-20230331737-A1 | MTORC1 MODULATORS AND USES THEREOF | MTOR, RPTOR, RICTOR | HRH3 3604/4885HRH2 3841/4885HRH1 3419/4885 |
| US-11759458-B2 | Indane-amines as PD-L1 antagonists | CD274, PDCD1LG2, PDCD1 | HRH3 11/4885HRH2 21/4885HRH1 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.